Liryc spin-offs and startups

Supporting the creation of startups

As part of its innovation policy, Liryc hosts and supports the creation of startups resulting from the research work of its teams.

Liryc now has four startups and many other projects are underway.

The institute offers a unique environment, with its cutting-edge technological platforms, its research and clinical teams and its scientific backing, conducive to fast-tracking the fulfilment of ideas for the benefit of patients. These startups are at the crossroads between research and care.

Beyond the transformation of research results into innovations and diagnostic or therapeutic solutions, Liryc and its partners enable job creation within the resulting startups and the creation of economic value reinvested in the activities of institute research.

Four spin-offs and a startup at Liryc


Founded in July 2017, the startup develops 3D virtual heart modelling and localization technology to enable more efficient and safer cardiac interventions.

Like a “google map” of cardiac interventions for arrhythmias, inHeart helps plan and guide clinicians. In procedures that are performed without opening the chest, this technology guides the instruments inside the heart to burn the areas causing abnormal electrical activity.

For further information, please visit:


Founded in November 2019, Certis Therapeutics designs innovative solutions for the treatment of cardiac pathologies, cancers and neurological disorders. These solutions combine software elements, including advanced image processing modules and thermal ablation devices. Certis Therapeutics is the only player in the market to offer a real-time thermometry solution on moving parts.

The tool is used to control, with unprecedented precision, minimally invasive thermal ablation therapies that aim to destroy pathological tissues using thermal energy.

For further information, please visit:


The biotech firm OP2 Drugs was founded in 2015 on the basis of very promising work on the effectiveness of a molecule already known elsewhere, and whose mode of action is of major interest in several pathologies, particularly in cardiology. Protected by several patents, this molecule, called OP2 113, is mainly developed for the prevention and treatment of the adverse effects of myocardial infarction, a disease responsible for more than 1,200,000 deaths per year in Europe and the United States.

For further information, please visit:


CareLine Solutions was designed and developed in 2018 by cardiologists from the private and public sectors. In partnership with the Liryc Institute, it has set itself the task of meeting the triple target of improving patient prognosis, optimizing medical time and innovation, by using remote monitoring data in an ambitious artificial intelligence research programme.

For further information, please visit:


Juliette a été victime d’une mort subite cardiaque provoquée par un dysfonctionnement de son coeur. Grâce aux découvertes et aux innovations scientifiques de l’Institut Liryc, elle a pu être sauvée. Ne laissons pas les maladies du rythme cardiaque emporter des vies.

This site is registered on as a development site. Switch to a production site key to remove this banner.